Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Overview of attention for article published in Clinical Cancer Research, October 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#8 of 17,708)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 53 news outlets
blogs: 4 blogs
twitter: 226 X users

facebook: 5 Facebook pages
wikipedia: 5 Wikipedia pages
reddit: 4 Redditors

Readers on

mendeley: 89 Mendeley

So far, Altmetric has seen 236 X posts from 226 X users, with an upper bound of 1,061,759 followers.

RT @erlesen: Anti-tumour immunity following intravesical Coxsackievirus A21 https://t.co/1Zl83qeOYr A strain of the common cold virus has b…

RT @ajitjohnson_n: Bladder cancer infected and eliminated by a strain of common cold virus. Study found that all signs of cancer disappeare…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 232 additional X posts.